/VTGN
VTGN Stock - VistaGen Therapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$0.78+5.11%
+$0.04 (+5.11%) • Dec 19
70
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.20
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.98
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+495.3%upside
Target: $4.63
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for VTGN
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.77 – $0.79
TARGET (TP)$4.63
STOP LOSS$0.72
RISK/REWARD1:66.6
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.56
52W High$5.14
52W Low$0.68
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $486,000 | $1.06M | $-227,000 | $1.11M | $1.09M |
| Gross Profit | $486,000 | $1.06M | $-227,000 | $1.11M | $1.09M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Income | $-55,973,000 | $-33,021,000 | $-59,268,000 | $-47,778,900 | $-17,933,800 |
| Net Income | $-51,418,000 | $-29,362,000 | $-59,248,000 | $-47,762,400 | $-17,934,200 |
| Net Margin | -10579.8% | -2759.6% | 26100.4% | -4307.2% | -1646.1% |
| EPS | $-1.67 | $-1.52 | $-8.51 | $-7.38 | $-14.74 |
Company Overview
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product candidature also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, and panic disorders. The company's CNS pipeline also comprises PH10, a rapid-onset neuroactive nasal spray, which is in preparation for Phase 2B clinical development as a stand-alone treatment for major depressive disorder (MDD); and AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is in development in combination with oral probenecid as a potential treatment of levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. It has contract research and development agreement with Cato Research Ltd.; license agreement with Pherin Pharmaceuticals, Inc.; and license and collaboration agreement with EverInsight Therapeutics Inc. VistaGen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
2
29%
Hold / Neutral
5
71%
Sell / Underperform
0%
Analyst Consensus🔴 Bearish
2 Bullish5 Neutral/Bearish
Price Targets
$12
Average Target
↑ 1407.5% Upside
Now
$1
Low
$12
Average
$30
High
Based on 4 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 17th 2025 | Jefferies | Downgrade | Hold | $0.9 |
| December 17th 2025 | Maxim Group | Downgrade | Hold | - |
| December 17th 2025 | William Blair | Downgrade | Market Perform | - |
| December 17th 2025 | Stifel | Downgrade | Hold | $1 |
| December 7th 2023 | Jefferies | Upgrade | Buy | $15 |
| August 7th 2023 | Maxim Group | Upgrade | Buy | $30 |
| July 22nd 2022 | Robert W. Baird | Downgrade | Neutral | - |
| July 22nd 2022 | Jefferies | Downgrade | Hold | - |
| July 22nd 2022 | William Blair | Downgrade | Market Perform | - |
Earnings History & Surprises
VTGNBeat Rate
47%
Last 19 quarters
Avg Surprise
-13.3%
EPS vs Estimate
Beats / Misses
9/8
2 met exactly
Latest EPS
$-0.54
Q4 2025
EPS Surprise History
Q1 24
+29.0%
$-0.22vs$-0.31
Q2 24
+26.5%
$-0.25vs$-0.34
Q3 24
+14.6%
$-0.35vs$-0.41
Q4 24
-5.0%
$-0.42vs$-0.40
Q1 25
+4.2%
$-0.46vs$-0.48
Q2 25
+17.3%
$-0.43vs$-0.52
Q3 25
0.0%
$-0.47vs$-0.47
Q4 25
-5.9%
$-0.54vs$-0.51
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Feb 12, 2026 | $-0.32 | — | — | — |
Q4 2025 | Nov 13, 2025 | $-0.51 | $-0.54 | -5.9% | ✗ MISS |
Q3 2025 | Aug 7, 2025 | $-0.47 | $-0.47 | 0.0% | = MET |
Q2 2025 | Jun 17, 2025 | $-0.52 | $-0.43 | +17.3% | ✓ BEAT |
Q1 2025 | Feb 13, 2025 | $-0.48 | $-0.46 | +4.2% | ✓ BEAT |
Q4 2024 | Nov 7, 2024 | $-0.40 | $-0.42 | -5.0% | ✗ MISS |
Q3 2024 | Aug 13, 2024 | $-0.41 | $-0.35 | +14.6% | ✓ BEAT |
Q2 2024 | Jun 11, 2024 | $-0.34 | $-0.25 | +26.5% | ✓ BEAT |
Q1 2024 | Feb 13, 2024 | $-0.31 | $-0.22 | +29.0% | ✓ BEAT |
Q4 2023 | Nov 9, 2023 | $-0.68 | $-0.66 | +2.9% | ✓ BEAT |
Q3 2023 | Aug 10, 2023 | $-0.86 | $-0.94 | -9.3% | ✗ MISS |
Q2 2023 | Jun 22, 2023 | $-1.50 | $-1.75 | -16.7% | ✗ MISS |
Q1 2023 | Feb 7, 2023 | $-1.80 | $-1.50 | +16.7% | ✓ BEAT |
Q4 2022 | Nov 10, 2022 | $-2.40 | $-2.40 | 0.0% | = MET |
Q3 2022 | Aug 11, 2022 | $-2.70 | $-3.00 | -11.1% | ✗ MISS |
Q2 2022 | Jun 23, 2022 | $-1.80 | $-2.40 | -33.3% | ✗ MISS |
Q1 2022 | Feb 10, 2022 | $-2.40 | $-1.50 | +37.5% | ✓ BEAT |
Q4 2021 | Nov 10, 2021 | $-1.50 | $-2.10 | -40.0% | ✗ MISS |
Q3 2021 | Aug 12, 2021 | $-1.50 | $-1.20 | +20.0% | ✓ BEAT |
Q2 2021 | Jun 29, 2021 | $-1.50 | $-6.01 | -300.7% | ✗ MISS |
Latest News
William Blair Downgrades Vistagen Therapeutics to Market Perform
📉 NegativeBenzinga•Dec 17, 2025, 09:17 PM
Maxim Group Downgrades Vistagen Therapeutics to Hold
📉 NegativeBenzinga•Dec 17, 2025, 08:46 PM
Jefferies Downgrades Vistagen Therapeutics to Hold, Lowers Price Target to $0.9
📉 NegativeBenzinga•Dec 17, 2025, 08:36 PM•Also:
Vistagen Therapeutics shares are trading lower after the company announced PALISADE-3 Phase 3 study did not achieve its primary endpoint.
📉 NegativeBenzinga•Dec 17, 2025, 02:11 PM
Trading Halt: Halt status updated at 8:45:00 AM ET: Quotation Resumption: News and Resumption Times
➖ NeutralBenzinga•Dec 17, 2025, 01:45 PM
Vistagen Says PALISADE-3 Phase 3 Study Of Intranasal Fasedienol For Acute Treatment Of Social Anxiety Disorder Did Not Demonstrate Statistically Significant Improvement On Primary Endpoint Of Change On SUDS
📉 NegativeBenzinga•Dec 17, 2025, 01:39 PM
Trading Halt: Halted at 8:25:00 a.m. ET - Trading Halt: Halt News Pending
➖ NeutralBenzinga•Dec 17, 2025, 01:25 PM
Vistagen Appoints Nick Tressler As CFO, Effective Immediately
➖ NeutralBenzinga•Dec 1, 2025, 01:36 PM
Vistagen Presents Data Showing PH80's Potential As Rapid Intranasal Treatment For Menopause Hot Flashes, At The Menopause Society 2025 Annual Meeting
📈 PositiveBenzinga•Nov 26, 2025, 01:37 PM
VistaGen Therapeutics Q2 EPS $(0.54) Misses $(0.48) Estimate, Sales $258.000K Beat $243.333K Estimate
➖ NeutralBenzinga•Nov 13, 2025, 09:32 PM
Vistagen Last Patient In PALISADE-3 Phase 3 Study Completes Trial For Evaluation Of Fasedienol To Treat Social Anxiety Disorder
➖ NeutralBenzinga•Nov 3, 2025, 01:42 PM
Vistagen Therapeutics' CFO Cynthia L. Anderson Resigns Effective October 15, 2025
📉 NegativeBenzinga•Sep 15, 2025, 08:56 PM
Frequently Asked Questions about VTGN
What is VTGN's current stock price?
VistaGen Therapeutics, Inc. (VTGN) is currently trading at $0.78 per share. The stock has moved +5.11% today.
What is the analyst price target for VTGN?
The average analyst price target for VTGN is $4.63, based on 1 analyst.
What sector is VistaGen Therapeutics, Inc. in?
VistaGen Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is VTGN's market cap?
VistaGen Therapeutics, Inc. has a market capitalization of $0.03 billion, making it a small-cap company.
Does VTGN pay dividends?
No, VistaGen Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorABOS
Acumen Pharmaceuticals, Inc.
$2.15
Mkt Cap: $0.1B
ACTU
Actuate Therapeutics Inc
$6.98
Mkt Cap: $0.2B
AGEN
Agenus Inc.
$3.44
Mkt Cap: $0.1B
CGTX
Cognition Therapeutics, Inc.
$1.54
Mkt Cap: $0.1B
HURA
TuHURA Biosciences, Inc.
$0.82
Mkt Cap: $0.0B
INO
Inovio Pharmaceuticals, Inc.
$2.28
Mkt Cap: $0.1B
IRD
Opus Genetics, Inc.
$2.00
Mkt Cap: $0.1B
MCRB
Seres Therapeutics, Inc.
$14.98
Mkt Cap: $0.1B
SEER
Seer, Inc.
$1.79
Mkt Cap: $0.1B
SPRO
Spero Therapeutics, Inc.
$2.32
Mkt Cap: $0.1B
Explore stocks similar to VTGN for comparison